Should I Buy Veeva (VEEV)? Finance YouTuber Analysis

The analyst is bullish on Veeva Systems, considering it a high-quality business trading at a very fair multiple. He highlights its double-digit revenue and profit growth, pristine balance sheet with significant net cash, and strong free cash flow generation. He believes the current enterprise value to free cash flow multiple of 12.5 is historically low and unjustified given its strong fundamentals.

“So surprisingly I do actually agree with Michael Bur on this one and I do think that this stock is looking interesting. It's looking cheap and it does look like a highquality business trading for a very fair multiple.”

The YouTuber explains Michael Burry's rationale for buying Veeva Systems, a cloud software provider for life sciences, after its stock dropped. Burry believes the market has overstated the competitive threat from Salesforce and that Veeva is trading at historically low price-to-earnings and price-to-sales multiples, making it an undervalued opportunity.

“He said the Salesforce threat is only relevant to a small part of its business. The significance has been far overstated.”

The YouTuber added to Veeva, which he describes as the cloud service for the pharmaceutical industry, as part of a rebalancing due to the impact of agentic AI.

“and I also added to Viva which is basically the cloud service for the pharmaceutical industry. Still debating on what I think about that based on the position size”

The YouTuber considers Viva 'robust' because it serves as the system of record for clinical trials, where errors would be existential for life sciences companies. This deterministic nature makes it highly resistant to AI disruption.

“Viva I think definitely has the system of record for clinical trials and missing messing up any one part of that is going to be existential to a life sciences company that's using it. So I don't see that going anywhere.”

The analyst purchased Veeva Systems, a niche CRM provider for the life sciences industry, due to its strong recurring revenue model (over 80% from subscriptions) and significant free cash flow. Despite a recent underperformance, the stock is currently trading at a historically low P/E ratio, suggesting undervaluation and an attractive expected annual return of 13%.

“insofern halte ich die Aktie auch für sehr interessant”